High‐performance thin‐layer chromatography has the capacity to run many samples simultaneously and reduced solvent usage. It offers a number of advantages that can save both time and money. The simultaneous quantification of fluticasone propionate and olopatadine hydrochloride in nasal spray has been developed and validated using a specific, precise, accurate, and economical high‐performance thin‐layer chromatography technique. Methanol:water:glacial acetic acid (8:2:0.05, v/v/v) was used as the mobile phase during the separation, which took place on a stationary phase of pre‐coated silica gel aluminum plate 60 F254. At 232 nm, separated components were densitometrically measured. The method was validated for linearity and range, precision, reproducibility, specificity, accuracy, the limit of detection, and the limit of quantification as per the International Council for Harmonization Q2(R1) guideline. Fluticasone propionate and olopatadine hydrochloride regression coefficients (R2) were found to be 0.9996 and 0.9991, accordingly. Fluticasone propionate and olopatadine hydrochloride percentage recoveries were measured to be 101.6 ± 0.69 and 99.62 ± 0.54, respectively. The analytical findings demonstrate that the proposed approach could be used to quantify Fluticasone propionate and olopatadine hydrochloride simultaneously in Pharmaceutical formulations.

High‐performance thin‐layer chromatography has the capacity to run many samples simultaneously and reduced solvent usage, It offers a number of advantages that can save both time and money. The simultaneous quantification of mometasone furoate and olopatadine hydrochloride in a combined dose has been developed and validated using a specific, precise, accurate, and economical high‐performance thin‐layer chromatography technique. Methanol: Water (8: 2, v/v) was used as the mobile phase during the separation, which took place on a stationary phase of pre‐coated silica gel aluminum plate 60 F254. At 248 nm, separated components were densitometrically measured. The method was validated for Linearity and range, precision, reproducibility, specificity, accuracy, the limit of detection, and the limit of quantification as per the International Council for Harmonization Q2(R1) guideline. mometasone furoate and olopatadine hydrochloride regression coefficients (R2) were found to be 0.9995 and 0.9991, accordingly. Mometasone furoate and olopatadine hydrochloride percentage recoveries were measured to be 98.99 ± 0.39 and 99.15 ± 0.95, respectively. The analytical findings demonstrate that the proposed approach could be used to quantify mometasone furoate and olopatadine HCl simultaneously in a combined dose.

High‐performance thin‐layer chromatography offers a variety of benefits that may assist you to save time and money, notably the capacity to run multiple samples at once and its reduced solvent usage. In alignment with the needs of molecular chemistry, it was also employed to modify and derivatize the stationary phase. Using a precise, accurate, as well as affordable high‐performance thin‐layer chromatography approach, the simultaneous measurement method for Doxycycline monohydrate and Ornidazole in the formulation has been developed and validated. Methanol: Iso‐propyl alcohol: Triethylamine (8:1.5:0.5, v/v/v) was used as the mobile phase during the separation, which took place on a stationary phase of pre‐treated derivatized silica gel aluminum plate 60 F254. At 285 nm, separated components were densitometrically measured. The method was validated for Linearity and range, precision, reproducibility, accuracy, the limit of detection, the limit of quantification, and robustness as per the International Council for Harmonization Q2(R1) guideline. Doxycycline monohydrate and Ornidazole regression coefficients (R2) were found to be 0.9967 and 0.9964, accordingly. Doxycycline monohydrate and Ornidazole percentage recoveries were measured to be 99.74 ± 0.65 and 100.8 ± 1.17, respectively. The analytical findings demonstrate that the proposed approach could be used to quantify Doxycycline monohydrate and Ornidazole simultaneously in pharmaceutical formulation.